Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1

FASEB Journal

Volumn 23, Issue 1, 2009, Pages 279-287

  Tan, Lindi ^a   Sarkis, Phuong Thi Nguyen ^a   Wang, Tao ^a   Tian, Chunjuan ^a   Yu, Xiao Fang ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antiviral; Evolution; G to A hypermutation; L1; Vif; Virus

Indexed keywords

APOBEC3H PROTEIN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CYTIDINE DEAMINASE; INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; RETROPOSON;

ALU ELEMENTS; CELL LINE; CYTOSINE DEAMINASE; HIV-1; HUMANS; ISOENZYMES; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; RETROELEMENTS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 58249114897     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.07-088781     Document Type: Article

References (85)

1. Bieniasz, P. D. (2004) Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5, 1109-1115
2. Goff, S. P. (2004) Retrovirus restriction factors. Mol. Cell 16, 849-859
3. Harris, R. S., and Liddament, M. T. (2004) Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4, 868-877
4. Navarro, F., and Landau, N. R. (2004) Recent insights into HIV-1 Vif. Curr. Opin. Immunol. 16, 477-482
5. Rogozin, I. B., Basu, M. K., Jordan, I. K., Pavlov, Y. I., and Koonin, E. V. (2005) APOBEC4, a new member of the AID/ APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4, 1281-1285
6. Rose, K. M., Marin, M., Kozak, S. L., and Kabat, D. (2004) Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279, 41744-41749
7. Turelli, P., and Trono, D. (2005) Editing at the crossroad of innate and adaptive immunity. Science 307, 1061-1065
8. Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S. J., and Malim, M. H. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396
9. Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O'Shea, K., S., Moran, J. V., and Cullen, B. R. (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103, 8780-8785
10. Chen, H., Lilley, C. E., Yu, Q., Lee, D. V., Chou, J., Narvaiza, I., Landau, N. R., and Weitzman, M. D. (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16, 480-485
11. Chiu, Y. L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., Heidmann, T., and Greene, W. C. (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103, 15588-15593
12. Doehle, B. P., Schafer, A., and Cullen, B. R. (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288
13. Esnault, C., Millet, J., Schwartz, O., and Heidmann, T. (2006) Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34, 1522-1531
14. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., Heidmann, T., and Schwartz, O. (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430-433
15. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809
16. Hulme, A. E., Bogerd, H. P., Cullen, B. R., and Moran, J. V. (2007) Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390, 199-205
17. Kobayashi, M., Takaori-Kondo, A., Shindo, K., Abudu, A., Fukunaga, K., and Uchiyama, T. (2004) APOBEC3G targets specific virus species. J. Virol. 78, 8238-8244
18. Kremer, M., Bittner, A., and Schnierle, B. S. (2005) Human APOBEC3G incorporation into murine leukemia virus particles. Virology 337, 175-182
19. Langlois, M. A., Beale, R. C., Conticello, S. G., and Neuberger, M. S. (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33, 1913-1923
20. Lecossier, D., Bouchonnet, F., Clavel, F., and Hance, A. J. (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112
21. Liddament, M. T., Brown, W. L., Schumacher, A. J., and Harris, R. S. (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14, 1385-1391
22. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103
23. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H., and Landau, N. R. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31
24. Muckenfuss, H., Hamdorf, M., Held, U., Perkovic, M., Lower, J., Cichutek, K., Flory, E., Schumann, G. G., and Munk, C. (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281, 22161-22172
25. Noguchi, C., Ishino, H., Tsuge, M., Fujimoto, Y., Imamura, M., Takahashi, S., and Chayama, K. (2005) G to A hypermutation of hepatitis B virus. Hepatology 41, 626-633
26. Rosler, C., Kock, J., Malim, M. H., Blum, H. E., and von Weizsacker, F. (2004) Comment on "Inhibition of hepatitis B virus replication by APOBEC3G." Science 305, 1403
27. Schumacher, A. J., Nissley, D. V., and Harris, R. S. (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. U. S. A. 102, 9854-9859
28. Stenglein, M. D., and Harris, R. S. (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281, 16837-16841
29. Suspene, R., Guetard, D., Henry, M., Sommer, P., Wain-Hobson, S., and Vartanian, J. P. (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102, 8321-8326
30. Suspene, R., Sommer, P., Henry, M., Ferris, S., Guetard, D., Pochet, S., Chester, A., Navaratnam, N., Wain-Hobson, S., and Vartanian, J. P. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32, 2421-2429
31. Turelli, P., Mangeat, B., Jost, S., Vianin, S. and Trono, D. (2004) Response to comment on "Inhibition of hepatitis B virus replication by APOBEC3G." Science 305, 1403b
32. Turelli, P., Mangeat, B., Jost, S., Vianin, S., and Trono, D. (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829
33. Wiegand, H. L., Doehle, B. P., Bogerd, H. P., and Cullen, B. R. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451-2458
34. Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D., and Landau, N. R. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279, 53379-53386
35. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M., and Landau, N. R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442
36. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98
37. Zheng, Y. H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., and Peterlin, B. M. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076
38. Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., and Strebel, K. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81, 13346-13353
39. Schumacher, A. J., Hache, G., Macduff, D. A., Brown, W. L., and Harris, R. S. (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82, 2652-2660
40. Guo, F., Cen, S., Niu, M., Saadatmand, J., and Kleiman, L. (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11710-11722
41. Bishop, K. N., Holmes, R. K., and Malim, M. H. (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80, 8450-8458
42. Mbisa, J. L., Barr, R., Thomas, J. A., Vandegraaff, N., Dorweiler, I. J., Svarovskaia, E. S., Brown, W. L., Mansky, L. M., Gorelick, R. J., Harris, R. S., Engelman, A., and Pathak, V. K. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099-7110
43. Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., and Yu, X. F. (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248
44. Kaiser, S. M., and Emerman, M. (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80, 875-882
45. Schrofelbauer, B., Yu, Q., Zeitlin, S. G., and Landau, N. R. (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79, 10978-10987
46. Yang, B., Chen, K., Zhang, C., Huang, S., and Zhang, H. (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11667-11675
47. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060
48. Mehle, A., Goncalves, J., Santa-Marta, M., McPike, M., and Gabuzda, D. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866
49. Yu, Y., Xiao, Z., Ehrlich, E. S., Yu, X., and Yu, X. F. (2004) Selective assembly of HIV-1 Vif-Cul5-elonginB-elonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18, 2867-2872
50. Luo, K., Xiao, Z., Ehrlich, E., Yu, Y., Liu, B., Zheng, S., and Yu, X. F. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102, 11444-11449
51. Mehle, A., Thomas, E. R., Rajendran, K. S., and Gabuzda, D. (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281, 17259-17265
52. Xiao, Z., Ehrlich, E., Yu, Y., Luo, K., Wang, T., Tian, C., and Yu, X. F. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349, 290-299
53. Xiao, Z., Ehrlich, E., Luo, K., Xiong, Y., and Yu, X. F. (2007) Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21, 217-222
54. Liu, B., Sarkis, P. T., Luo, K., Yu, Y., and Yu, X. F. (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79, 9579-9587
55. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403
56. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407
57. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2003) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798
58. Shirakawa, K., Takaori-Kondo, A., Kobayashi, M., Tomonaga, M., Izumi, T., Fukunaga, K., Sasada, A., Abudu, A., Miyauchi, Y., Akari, H., Iwai, K., and Uchiyama, T. (2006) Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 344, 263-266
59. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013
60. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6
61. Tian, C., Yu, X., Zhang, W., Wang, T., Xu, R., and Yu, X. F. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80, 3112-3115
62. Schrofelbauer, B., Senger, T., Manning, G., and Landau, N. R. (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80, 5984-5991
63. Russell, R. A., and Pathak, V. K. (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210
64. He, Z., Zhang, W., Chen, G., Xu, R., and Yu, X. F. (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381, 1000-1011
65. Conticello, S. G., Thomas, C. J., Petersen-Mahrt, S. K., and Neuberger, M. S. (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22, 367-377
66. OhAinle, M., Kerns, J. A., Malik, H. S., and Emerman, M. (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80, 3853-3862
67. Sawyer, S. L., Emerman, M., and Malik, H. S. (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2, E275
68. Dang, Y., Wang, X., Esselman, W. J., and Zheng, Y. H. (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10522-10533
69. Niewiadomska, A. M., Tian, C., Tan, L., Wang, T., Sarkis, P. T., and Yu, X. F. (2007) Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J. Virol. 81, 9577-9583
70. Luo, K., Liu, B., Xiao, Z., Yu, Y., Yu, X., Gorelick, R., and Yu, X. F. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78, 11841-11852
71. Applied Biosystems (1997) ABI Prism 7700 User Bulletin Number 2, pp. 11-15, Applied Biosystems, Foster City, CA, USA
72. Ostertag, E. M., Prak, E. T., DeBerardinis, R. J., Moran, J. V., and Kazazian, H. H., Jr. (2000) Determination of L1 retrotransposition kinetics in cultured cells. Nucleic Acids Res. 28, 1418-1423
73. Turelli, P., Vianin, S., and Trono, D. (2004) The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 279, 43371-43373
74. Kinomoto, M., Kanno, T., Shimura, M., Ishizaka, Y., Kojima, A., Kurata, T., Sata, T., and Tokunaga, K. (2007) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 35, 2955-2964
75. Brouha, B., Schustak, J., Badge, R. M., Lutz-Prigge, S., Farley, A. H., Moran, J. V., and Kazazian, H. H., Jr. (2003) Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl. Acad. Sci. U. S. A. 100, 5280-5285
76. Moran, J. V., Holmes, S. E., Naas, T. P., DeBerardinis, R. J., Boeke, J. D., and Kazazian, H. H., Jr. (1996) High frequency retrotransposition in cultured mammalian cells. Cell 87, 917-927
77. Dewannieux, M., Esnault, C., and Heidmann, T. (2003) LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 35, 41-48
78. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J., Mesirov, J. P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange-Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J. C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R. H., Wilson, R. K., Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A., Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C., Delehaunty, K. D., Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L., Fulton, R. S., Johnson, D. L., Minx, P. J., Clifton, S. W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, J. F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921
79. + T cells. Nature 435, 108-114
80. Peng, G., Lei, K. J., Jin, W., Greenwell-Wild, T., and Wahl, S. M. (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203, 41-46
81. Tanaka, Y., Marusawa, H., Seno, H., Matsumoto, Y., Ueda, Y., Kodama, Y., Endo, Y., Yamauchi, J., Matsumoto, T., Takaori-Kondo, A., Ikai, I., and Chiba, T. (2006) Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem. Biophys. Res. Commun. 341, 314-319
82. Sarkis, P. T., Ying, S., Xu, R., and Yu, X. F. (2006) STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177, 4530-4540
83. Ying, S., Zhang, X., Sarkis, P. T., Xu, R., and Yu, X. (2007) Cell-specific Regulation of APOBEC3F by Interferons. Acta Biochim. Biophys. Sin. (Shanghai) 39, 297-304
84. Bonvin, M., Achermann, F., Greeve, I., Stroka, D., Keogh, A., Inderbitzin, D., Candinas, D., Sommer, P., Wain-Hobson, S., Vartanian, J. P., and Greeve, J. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364-1374
85. Dang, Y., Siew, L. M., Wang, X., Han, Y., Lampen, R., and Zheng, Y. H. (2008) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283, 11606-11614